The complexity of neoplasia and its treatment are a challenge to the formulation of general
criteria that are applicable across solid cancers. Determining the number of prior lines of …

Composite outcome measures such as progression-free survival and disease-free survival
are increasingly used as surrogate end points in oncology research, frequently serving as …

Progression-free survival (PFS) is an end-point in an increasing number of cancer clinical
trials, informing both regulatory bodies and clinical practice. PFS is utilised both as a …

Recommending the most effective treatment that scientific evidence can support is a
fundamental goal of oncologic practice. However, as every oncologist knows, providing such …

The value of any new therapeutic strategy or treatment is determined by the magnitude of its
clinical benefit balanced against its cost. Evidence for clinical benefit from new treatment …

Purpose: To establish the concept of minimum clinically meaningful outcome (mCMO) of
treatment in advanced solid tumors, to establish its threshold and evaluate how many …

Introduction Molecular-matched therapies have revolutionized cancer treatment. We
evaluated the improvement in clinical outcomes of applying an in-house customized Next …

Progression-free survival (PFS) is increasingly used as an important and even a primary
endpoint in randomized cancer clinical trials in the evaluation of patients with solid tumors …

Progression-free survival (PFS) is an increasingly important end-point in cancer drug
development. However, several concerns exist regarding the use of PFS as a basis to …

Cancer therapy has been characterized throughout history by ups and downs, not only due
to the ineffectiveness of treatments and side effects, but also by hope and the reality of …